B
HAE icon

Bailard’s Haemonetics HAE Stock Holding History

Bailard’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,835
Closed -$254K – 757
2023
Q3 		$254K Buy
2,835
+300
+12% +$26.8K 0.01% 588
2023
Q2 		$216K Buy
+2,535
New +$214K 0.01% 629
2018
Q3 		– Sell
-6,350
Closed -$569K – 540
2018
Q2 		$569K Sell
6,350
-25
-0.4% -$2.11K 0.03% 333
2018
Q1 		$466K Buy
+6,375
New +$437K 0.03% 332

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bailard's HAE Position: Q4 2023 in Review

Bailard sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 2,835 shares — an estimated $254K sold.

Bailard first reported a position in HAE in Q1 2018 and held it in 4 quarters. The position peaked at $569K in Q2 2018. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

  • Bailard reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
  • Bailard sold 2,835 Haemonetics shares in Q4 2023, an estimated $254K.
  • Bailard first reported a position in Haemonetics in Q1 2018 and held it in 4 quarters.
  • Bailard's Haemonetics position peaked at $569K in Q2 2018.
  • 295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Bailard's 13F filing for Q4 2023, filed 2 Feb 2024.